REVE Technologies, Inc (BSSP)

[bow-tie]

Enzolytics, Inc. Files Provisional Patent for Treatment of ...
www.benzinga.com/pressreleases/20/12/ac18739288/...
1 day ago · Enzolytics' flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective Enzolytics' flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.e in the treatment of HIV/AIDS.
https://www.benzinga.com/pressreleases/20/12/ac18739288/enzolytics-inc-files-provisional-patent-for-treatment-of-multiple-sclerosis



Enzolytics, Inc. Files Provisional Patent for Treatment of Multiple Sclerosis
ACCESSWIRE FOLLOW
December 10, 2020 1:30pm
https://www.benzinga.com/pressreleases/20/12/ac18739288/enzolytics-inc-files-provisional-patent-for-treatment-of-multiple-sclerosis

PLANO, TX / ACCESSWIRE / December 10, 2020 / Enzolytics, Inc. (OTC:ENZC, Company", )) today announced the filing of a provisional patent with the U.S. Patent Office on December 9, 2020 for a treatment of Multiple Sclerosis developed by Harry Zhabilov, titled NUCLEAR PROTEINS ISOLATED FROM MAMALIAN SPINAL CORD (SCNP) IMMUNE FACTOR, Ser. No. 62/123341. The Company received confirmation of filing from the U.S. Patent Office today.